Barbara Seliger , Markus J Maeurer , Soldano Ferrone
{"title":"Antigen-processing machinery breakdown and tumor growth","authors":"Barbara Seliger , Markus J Maeurer , Soldano Ferrone","doi":"10.1016/S0167-5699(00)01692-3","DOIUrl":null,"url":null,"abstract":"<div><p>Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been described in tumors of different histology. Murine data suggest that defects in the MHC class II APM might also be associated with malignant transformation of human cells. This article describes the pathophysiology of the MHC class I and II APM, reviews APM abnormalities in tumor cells and discusses their role in the escape of tumor cells from <em>in vitro</em> recognition by T cells.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 9","pages":"Pages 455-464"},"PeriodicalIF":0.0000,"publicationDate":"2000-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01692-3","citationCount":"485","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology today","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167569900016923","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 485
Abstract
Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been described in tumors of different histology. Murine data suggest that defects in the MHC class II APM might also be associated with malignant transformation of human cells. This article describes the pathophysiology of the MHC class I and II APM, reviews APM abnormalities in tumor cells and discusses their role in the escape of tumor cells from in vitro recognition by T cells.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
